AstraZeneca coronavirus vaccine has shown, on average, 70% effectiveness, revealed a study conducted at the University of Oxford.
On Monday, Pharmaceutical giant AstraZeneca plc announced that its coronavirus vaccine being tested in a study at the University of Oxford has shown 70% effectiveness, with no major safety concerns to the patients.
According to a press release from the British-Swedish multinational biopharmaceutical company, the vaccine, named AZD1222, came out to be effective for preventing COVID-19, revealed during a study comprising 131 participants and in collaboration with the University of Oxford.
Read more: COVID-19: DUHS clinical trials of C-IVIG therapy show promising results
The experiment with positive results showed that “results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil” were not highly satisfied in preventing COVID-19 but that no hospitalizations or severe cases were reported among participants.
AstraZeneca said, “Two different dosing regimens demonstrated efficacy with one showing a better profile,” “One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart.”
The statement further reads, “The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%.”
The pharmaceutical said that it was now in a phase to seek approval for the drug so that it may be included in the World Health Organization’s (WHO) Emergency Use Listing.
The chief investigator of the Oxford Vaccine Trial, Professor Andrew Pollard says that the findings indicate that the “effective vaccine, will save many lives.”
Moreover, AstraZeneca Chief Executive Officer Pascal Soriot termed the development “an important milestone”, saying the coronavirus vaccine’s simple supply chain, as well the pharma giant’s commitment of no profit and timely access “means it will be affordable and globally available, supplying hundreds of millions of doses on approval”.
